BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ABBV-253 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ABBV-253\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07807956-11143@assetmemo.bio
DTSTAMP:20261121T004548Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:ABBV-253: Phase 1 readout est. (NCT07807956)
DESCRIPTION:ABBV-253\, phase 1\, Advanced Solid Tumors.\nStudy: A Study to 
 Assess Adverse Events\, Change in Disease Activity and How Intravenous ABB
 V-253 Moves Through the Body in Adult Participants With Advanced Solid Tum
 ors\nEstimated primary completion: December 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/abbv-253#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07807956
URL:https://assetmemo.bio/drug/abbv-253#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
